Update: DiscGenics Phase I/II Clinical Trial

DiscGenics IDCT Injection

DiscGenics presented positive interim data from its ongoing Phase I/II clinical trial of IDCT (injectable disc cell therapy) for the treatment of degenerative disc disease.

The primary efficacy endpoint of the study (n=60) was achieved, with statistically significant improvement in back pain observed in the high dose IDCT group. For these...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us